An iron‐catalyzed denitrogenative rearrangement of 1,2,3,4‐tetrazole is developed over the competitive C(sp3)–H amination. This catalytic rearrangement reaction follows an unprecedented metalloradical activation mechanism. Employing the developed method, a wide number of complex‐N‐heterocyclic product classes have been accessed. The synthetic utility of this radical activation method is showcased with
catalytic amount of Fe(TPP)Cl and Zn dust. The reaction precludes the traditional, more favored click reaction between an organic azide and alkynes, and instead proceeds by an unprecedented metalloradicalactivation. The method is anticipated to advance access to the construction of important basic nitrogen heterocycles, which will in turn enable discoveries of new drug candidates.
denitrogenative C(sp3)-Hamination of 1,2,3,4-tetrazoles bearing unactivated primary, secondary and tertiary C-H bonds is discovered. This cata-lytic amination follows an unprecedented metalloradical activation mechanism. The utility of the developed method is showcased with the short synthesis of a bioactive mole-cule. Moreover, an initial effort has been embarked for the enantioselective C(sp3)-H amination
Synthesis of Tetrazolo[1,5-<i>a</i>]pyridines Utilizing Trimethylsilyl Azide and Tetrabutylammonium Fluoride Hydrate
作者:Gregory Cuny、Joydev Laha
DOI:10.1055/s-0028-1083233
日期:2008.12
A method for the preparation of tetrazolo[1,5- A]pyridines from 2-halopyridines,utilizing trimethylsilyl azide in the presence of tetrabutylammoniumfluoride hydrate, is described. In addition, 8-bromotetrazolo[1,5- A]pyridine is further transformed intoa variety of novel tetrazolo[1,5- A]pyridinederivatives.
Disclosed in the present disclosure are an azaheteroaryl compound, a pharmaceutically acceptable salt thereof, and a solvate thereof. The present disclosure also provides a method for preparing said compound, a composition containing said compound, and a use of said compound in the preparation of a drug for treating a disease or disorder related to the mechanism of action of an EED protein and/or a PRC2 protein complex. (Formula 1)